Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| IRON | CLUSTER | bearish | 5/10 | Director Kevin Bitterman sold ~$4.4M of IRON stock in a concentrated 7-day cluster, while COO Jonathan Yu sold $731K. Th | Sep 3, 2026 |
| LTGO | PRESS-RELEASE | bullish | 7/10 | Latigo Biotherapeutics reported Q2 2026 results with a net loss of $25.8M (EPS -$27.59 vs consensus -$0.46, a mechanical | Sep 3, 2026 |
| KNSA | 144 | neutral | 2/10 | Officer Michael R. Megna filed a Form 144 to sell 4,600 Class A ordinary shares of Kiniksa Pharmaceuticals, with an appr | Sep 3, 2026 |
| KMDA | PRESS-RELEASE | neutral | 2/10 | Kamada announced a tax ruling from the Israel Tax Authority regarding its previously declared $0.17 per share cash divid | Sep 3, 2026 |
| KMDA | 6-K | neutral | 2/10 | Kamada obtained a tax ruling from the Israel Tax Authority clarifying withholding tax procedures for its previously anno | Sep 3, 2026 |
| BIAF | S-3/A | bearish | 7/10 | bioAffinity Technologies filed Amendment No. 1 to its S-3 shelf registration, registering 1,692,408 shares of common sto | Sep 3, 2026 |
| CANF | 6-K | mixed | 6/10 | Can-Fite BioPharma raised approximately $4.0 million in gross proceeds via a warrant inducement transaction. A holder ex | Sep 3, 2026 |
| GTBP | 8-K | neutral | 4/10 | GT Biopharma filed a Certificate of Amendment to effect a 1-for-25 reverse stock split and reduce authorized shares from | Sep 3, 2026 |
| APGE | 25-NSE | bullish | 8/10 | Apogee Therapeutics has been acquired by AbbVie in a completed all-cash merger valued at approximately $10.9 billion. Sh | Sep 3, 2026 |
| MRNA | ANALYST-DOWNGRADE | bearish | 6/10 | Rothschild & Co double downgraded Moderna from Neutral to Sell on Sep 3, 2026, slashing the price target from $40 to $81 | Sep 3, 2026 |
| SMMT | 8-K | bullish | 6/10 | Partner Akeso announced statistically significant overall survival (OS) benefit for ivonescimab monotherapy vs pembroliz | Sep 3, 2026 |
| APVO | 424B4, 8-K | mixed | 6/10 | Aptevo Therapeutics filed an 8-K announcing a 93% clinical benefit rate with its mipletamig triplet in frontline AML pat | Sep 3, 2026 |
| LBRX | 8-K | neutral | 4/10 | LB Pharmaceuticals appointed Joseph M. Miller as CFO, effective September 2, 2026. Miller brings relevant experience fro | Sep 3, 2026 |
| PRFX | 6-K | mixed | 6/10 | PRF Technologies (PRFX) reported H1 2026 results showing a net loss of $2.8M (up from $2.3M) but generated first-ever re | Sep 3, 2026 |
| ONCO | 425 | neutral | 3/10 | Onconetix filed a 425 communication announcing that its acquisition target, Realbotix LLC, has launched a pilot program | Sep 3, 2026 |
| ABBV | 8-K | neutral | 4/10 | AbbVie completed its $10.9 billion acquisition of Apogee Therapeutics, adding late-stage immunology assets zumilokibart | Sep 3, 2026 |
| JAGX | 424B5 | bearish | 5/10 | Jaguar Health filed Supplement No. 7 to its ATM prospectus, reducing the remaining capacity under its at-the-market offe | Sep 3, 2026 |
| APGE | 8-K | bullish | 8/10 | Apogee Therapeutics has been acquired by AbbVie in a completed all-cash merger valued at approximately $10.9 billion. Sh | Sep 3, 2026 |
| PRFX | PRESS-RELEASE | neutral | 4/10 | PRF Technologies reported a net loss of $2.8M for H1 2026 (up from $2.3M) but strengthened its cash position to $11.6M a | Sep 3, 2026 |
| MDCX | 8-K | bullish | 7/10 | Medicus Pharma Ltd. (MDCX) entered into a Co-Development and License Agreement with Pfizer Inc. for CD228V, an early cli | Sep 3, 2026 |
| LQDA | 8-K | bullish | 5/10 | Liquidia announced that the FDA granted Fast Track Designation to YUTREPIA (treprostinil) inhalation powder for the trea | Sep 3, 2026 |
| CLYM | 8-K | bullish | 7/10 | Climb Bio announced positive initial Phase 1 data for CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy (Ig | Sep 3, 2026 |
| PASG | S-4/A, 425 | bearish | 8/10 | Passage Bio filed an amended S-4 (S-4/A) detailing its proposed reverse merger with Remix Therapeutics, where Remix will | Sep 3, 2026 |
| APVO | EFFECT | bearish | 6/10 | Aptevo Therapeutics Inc. (APVO) filed an EFFECT notice on 2026-09-02, indicating that its S-1 registration statement (Fi | Sep 3, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a 6-K announcing CEO David Stamler will participate in a fireside chat at the Cantor Global | Sep 3, 2026 |
| IVA | 6-K | bullish | 7/10 | Inventiva announced the last patient completed the final 72-week visit in the pivotal NATiV3 Phase 3 trial of lanifibran | Sep 3, 2026 |
| EIKN | PRESS-RELEASE | neutral | 3/10 | Eikon Therapeutics appointed Dr. Ching-Pin Chang as EVP and Chief Scientific Officer. Dr. Chang joins from Bristol Myers | Sep 3, 2026 |
| ACIU | 6-K | neutral | 2/10 | AC Immune SA filed a 6-K announcing an Extraordinary General Meeting (EGM) on October 2, 2026, to elect Tom Graney to th | Sep 3, 2026 |
| HCM | 6-K | bullish | 7/10 | HUTCHMED announced an exclusive worldwide licensing agreement with GSK for HMPL-A830, a first-in-class KRAS-EGFR Antibod | Sep 3, 2026 |
| LQDA | PRESS-RELEASE | bullish | 6/10 | No summary provided | Sep 3, 2026 |